257 related articles for article (PubMed ID: 23831137)
1. Development and characterization of a non-cell-based assay to assess the presence of neutralizing antibodies to interferon-beta in clinical samples.
Cludts I; Meager A; Thorpe R; Wadhwa M
J Immunol Methods; 2013 Sep; 395(1-2):37-44. PubMed ID: 23831137
[TBL] [Abstract][Full Text] [Related]
2. Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.
Hegen H; Millonig A; Bertolotto A; Comabella M; Giovanonni G; Guger M; Hoelzl M; Khalil M; Killestein J; Lindberg R; Malucchi S; Mehling M; Montalban X; Polman CH; Rudzki D; Schautzer F; Sellebjerg F; Sørensen PS; Deisenhammer F
Mult Scler; 2014 Apr; 20(5):577-87. PubMed ID: 24009164
[TBL] [Abstract][Full Text] [Related]
3. Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis.
Gavasso S; Gjertsen B; Anderssen E; Myhr K; Vedeler C
Mult Scler; 2012 Aug; 18(8):1116-24. PubMed ID: 22287540
[TBL] [Abstract][Full Text] [Related]
4. Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: a comparison of three methods in a large Australasian cohort.
McKay F; Schibeci S; Heard R; Stewart G; Booth D
J Immunol Methods; 2006 Mar; 310(1-2):20-9. PubMed ID: 16448664
[TBL] [Abstract][Full Text] [Related]
5. Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice.
van der Voort LF; Kok A; Visser A; Oudejans CB; Caldano M; Gilli F; Bertolotto A; Polman CH; Killestein J
Mult Scler; 2009 Feb; 15(2):212-8. PubMed ID: 18805837
[TBL] [Abstract][Full Text] [Related]
6. Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice.
Farrell RA; Espasandin M; Lakdawala N; Creeke PI; Worthington V; Giovannoni G
Mult Scler; 2011 Nov; 17(11):1333-40. PubMed ID: 21685230
[TBL] [Abstract][Full Text] [Related]
7. Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.
Gilli F; Bertolotto A; Sala A; Hoffmann F; Capobianco M; Malucchi S; Glass T; Kappos L; Lindberg RL; Leppert D
Brain; 2004 Feb; 127(Pt 2):259-68. PubMed ID: 14607790
[TBL] [Abstract][Full Text] [Related]
8. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
[TBL] [Abstract][Full Text] [Related]
9. Neutralizing and binding antibodies to interferon beta in patients with multiple sclerosis: a comparison of assay results from three italian centres.
Bellomi F; Bramanti P; Trojano M; Scagnolari C; Muto A; Sessa E; La Volpe V; Russo P; Antonelli G
J Immunoassay Immunochem; 2009; 30(1):40-50. PubMed ID: 19117201
[TBL] [Abstract][Full Text] [Related]
10. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis.
Sørensen PS; Deisenhammer F; Duda P; Hohlfeld R; Myhr KM; Palace J; Polman C; Pozzilli C; Ross C;
Eur J Neurol; 2005 Nov; 12(11):817-27. PubMed ID: 16241970
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta.
Hermanrud C; Ryner M; Luft T; Jensen PE; Ingenhoven K; Rat D; Deisenhammer F; Sørensen PS; Pallardy M; Sikkema D; Bertotti E; Kramer D; Creeke P; Fogdell-Hahn A;
J Immunol Methods; 2016 Mar; 430():1-9. PubMed ID: 26779831
[TBL] [Abstract][Full Text] [Related]
12. Important sources of variability in clinical studies of neutralizing antibodies against interferon beta.
Hurwitz BJ
J Neurol Sci; 2008 Sep; 272(1-2):8-19. PubMed ID: 18620708
[TBL] [Abstract][Full Text] [Related]
13. Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial.
Goodin DS; Hartung HP; O'Connor P; Filippi M; Arnason B; Comi G; Cook S; Jeffery D; Kappos L; Bogumil T; Knappertz V; Sandbrink R; Beckmann K; White R; Petkau J; Pohl C;
Mult Scler; 2012 Feb; 18(2):181-95. PubMed ID: 21952094
[TBL] [Abstract][Full Text] [Related]
14. Antibodies against interferon-beta in multiple sclerosis.
Aarskog NK; Marøy T; Myhr KM; Vedeler CA
J Neuroimmunol; 2009 Jul; 212(1-2):148-50. PubMed ID: 19467718
[TBL] [Abstract][Full Text] [Related]
15. The clinical importance of neutralizing antibodies in relapsing-remitting multiple sclerosis.
Namaka M; Pollitt-Smith M; Gupta A; Klowak M; Vasconcelos M; Turcotte D; Gong Y; Melanson M
Curr Med Res Opin; 2006 Feb; 22(2):223-39. PubMed ID: 16466595
[TBL] [Abstract][Full Text] [Related]
16. Neutralizing antibodies, MxA expression and MMP-9/TIMP-1 ratio as markers of bioavailability of interferon-beta treatment in multiple sclerosis patients: a two-year follow-up study.
Garcia-Montojo M; Dominguez-Mozo MI; de las Heras V; Bartolome M; Garcia-Martinez A; Arroyo R; Alvarez-Lafuente R
Eur J Neurol; 2010 Mar; 17(3):470-8. PubMed ID: 20050906
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta.
Bertolotto A; Sala A; Caldano M; Capobianco M; Malucchi S; Marnetto F; Gilli F
J Immunol Methods; 2007 Apr; 321(1-2):19-31. PubMed ID: 17335844
[TBL] [Abstract][Full Text] [Related]
18. Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis?
Sorensen PS; Koch-Henriksen N; Bendtzen K
Mult Scler; 2007 Jun; 13(5):616-21. PubMed ID: 17548440
[TBL] [Abstract][Full Text] [Related]
19. The role of neutralizing antibodies to interferon-β as a biomarker of persistent MRI activity in multiple sclerosis: a 7-year observational study.
Paolicelli D; Manni A; Iaffaldano A; Di Lecce V; D'Onghia M; Iaffaldano P; Trojano M
Eur J Clin Pharmacol; 2016 Aug; 72(8):1025-9. PubMed ID: 27251359
[TBL] [Abstract][Full Text] [Related]
20. Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis.
Deisenhammer F; Schellekens H; Bertolotto A
J Neurol; 2004 Jun; 251 Suppl 2():II31-9. PubMed ID: 15264110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
